AUTHORS
Tabitha Ranson, MD, Drake Enderlin, MD2, Nikhil Verma, MD3, Vidhi Bhanushali, MBBS4, Clyde Bailey, BS5, Sharmilan Thanendrarajan, MD6, Maurizio Zangari, MD7, Frits van Rhee, MD, PhD8, Deukwoo Kwon, PhD9, Carolina D Schinke, MD10
AFFILIATIONS
1 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
2 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
3 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
4 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
5 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
6 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
7 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
8 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
9 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
10 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
ABSTRACT
Introduction: The addition of Talquetamab, a GPRC5D directed antibody, has improved survival in relapsed/refractory multiple myeloma (RRMM). However, optimal sequence of bispecific treatments remains unknown. Bispecific antibodies with a higher burden of toxicity and/or T-cell exhaustion may have the potential to influence response rates to sequential bispecific therapies. Understanding the ideal sequence of bispecific therapies could improve outcomes for RRMM. This study aimed to investigate response rates to a second bsAb after prior exposure to a BCMA or GPRC5D directed bispecific.
Methods: Using electronic medical records data, we conducted a single-center retrospective cohort study of all patients with RRMM who were treated with both BCMA (teclistamab) and GPRC5D (talquetamab) directed bispecific antibodies. Of the 47 total patients who met inclusion criteria, 16 patients received Talquetamab prior to Teclistimab and were labeled group 1. The remaining 31 patients received Teclistimab prior to treatment with Talquetamab and were labeled group 2. This retrospective review focused on clinical outcomes such as response rates, progression free (PFS) and overall survival (OS).
Results: A total of 47 patients were included, with 16 in group 1 and 31 in group 2. There were no significant differences in age (59 years), gender (68% male, n=32) and performance status (0-1 in 68%, n=32) between the 2 groups. There were significantly more Black Americans in group 1 (31% vs 16%, n=5/16 vs 5/31), p= 0.009. Cytogenetics were available in 41 patients and were similar between the groups with overall 15% having translocation t4;14 (n=6), 34% having deletion 17p (n=14) and 56% having duplication 1q (n=23). Extramedullary disease was present in 36% of all patients (n=17) and plasma cell leukemia in 9% (n=4) with no significant differences between groups. Median prior lines of therapy were 5 and 64% of patients (n=30) were penta-refractory with no significant differences between the groups. 53% of all patients had prior BCMA targeting CAR-T cell therapy (n=25) with no significant differences between groups. Time between first and second bsAb therapies was significantly longer in group 1 with 94 (43-311) days compared to group 2 with 38 (26-79) days, p=0.005. Absolute lymphocyte count (ALC) on day of step-up dosing to Teclistimab did not differ between groups with a median ALC of 1.11 (0.56-1.84) in group 1 and 0.91 (0.61-1.75) in group 2 (p=0.8). Similar results were seen to Talquetamab with median ALC of 1.11 (0.71-1.70) and 0.90 (0.46-1.37) in groups 1 and 2 respectively (p=0.5). Overall response rates (including CR/VGPR/PR) to first and second bsAb were 75% (31% CR, 25% VGPR and 19% PR) and 82% (50% CR, 13% VGPR and 19% PR) in group 1 and 61% (26% CR, 16% VGPR and 19% PR) and 71% (48% CR, 10% VGPR and 13% PR) in group 2 with no significant differences. In group 1, 62.5% of responders to initial talquetamab, also responded to subsequent teclistamab, while 50% of responders to initial teclistamab in group 2 also responded to subsequent talquetamab. Non-responders to the first bsAb that subsequently responded to the second bsAb were 18.8% patients in group 1 and 28.6% in group 2. 12-and 24-month PFS to talquetamab in group 1 was 12.5% and 0% respectively and 22.6% and 6.5% to teclistamab in group 2. 12-and 24-month PFS to subsequent teclistamab in group 1 was 51.6%/ 51.6% and 41.7%/27.8% to subsequent talquetamab in group 2 with no statistically significant differences. With a median follow up time of 30 months, the OS – counted from first bsAb treatment- was not reached for group 1 and was 26.3 months for group 2 (p=0.17).
Conclusion: While this study was small and did not show significant differences of outcomes between group 1 and 2, there are some important takeaways. First, response rates to the second bsAb after failing the first one remain high, in this study around 80%. Second, responders to the first bsAb had a higher chance to respond to the second bsAb, albeit up to 28.6% of patients with no response to the initial bsAb, responded to the second bsAb. Of further interest is also that 12 and 24 months PFS after the second bsAb seemed better than after the first bsAb in this patient cohort. The reasons for this are not quite clear and results should be confirmed in further studies.
DISCLOSURES
Tabitha Ranson, MD: No relevant conflicts of interest to declare.